Introduction: Patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL) have poor outcome. Time to first relapse or progression (POD) has been consistently shown to be an independent predictor of survival, with patients experiencing early-POD, within 2 years since the diagnosis, representing a subgroup at greater risk of death. On the contrary, there is a paucity of large-scale treatment data on patients experiencing relapse beyond 2 years (late-POD). Methods: In this international, observational cohor…